Form 4: Cumberland Pharma CEO Boosts Stake via 10b5-1 Plan
Insider Transaction Report
Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, increased his direct ownership of common stock through a series of pre-scheduled purchases under a Rule 10b5-1 plan.
Summary
- A.J. Kazimi, Chairman and CEO, Director, and 10% Owner of Cumberland Pharmaceuticals Inc. (CPIX), reported a series of common stock acquisitions.
- Transactions occurred daily from September 2, 2025, to September 30, 2025.
- A total of 242 shares were acquired over the period (19 transactions of 12 shares, 2 transactions of 13 shares).
- The purchases were made at prices ranging from $3.05 to $3.60 per share.
- All acquisitions were direct ownership and executed automatically pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.
- Following these transactions, A.J. Kazimi's direct beneficial ownership increased from 5,700,042 shares to 5,700,284 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is mildly positive due to insider buying, which generally signals confidence. However, the extremely small volume of shares purchased daily under a pre-scheduled plan limits the strength of this positive signal.
Positives
- The Chairman and CEO's continued acquisition of company stock, even in small amounts, demonstrates ongoing confidence in the company's future prospects.
- The purchases were made under a Rule 10b5-1 plan, indicating a pre-planned, systematic approach to increasing insider ownership.
Negatives
- The daily purchase volume of 12-13 shares is extremely small, limiting the significance of these transactions as a strong market signal.
- The stock price generally trended downwards during the reported purchase period, from $3.54 on September 2, 2025, to $3.12 on September 30, 2025.
Future Outlook
The filing does not provide any forward-looking statements or guidance beyond the reporting of past transactions under a pre-existing trading plan.
Industry Context
Insider buying, even in small volumes, can be interpreted as a signal of management's belief in the company's value, potentially boosting investor sentiment. However, the pharmaceutical industry is subject to various external factors, and these routine purchases do not provide specific insights into broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders may view the insider purchases as a positive sign of management's commitment and belief in the company's value, potentially increasing investor confidence.
Key Dates
| Date | Description |
|---|---|
| 11/14/2024 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 09/02/2025 | Earliest transaction date, 12 shares of Common Stock acquired at $3.54. |
| 09/03/2025 | 12 shares of Common Stock acquired at $3.58. |
| 09/04/2025 | 12 shares of Common Stock acquired at $3.60. |
| 09/05/2025 | 12 shares of Common Stock acquired at $3.60. |
| 09/08/2025 | 12 shares of Common Stock acquired at $3.41. |
| 09/09/2025 | 12 shares of Common Stock acquired at $3.43. |
| 09/10/2025 | 12 shares of Common Stock acquired at $3.39. |
| 09/11/2025 | 12 shares of Common Stock acquired at $3.41. |
| 09/12/2025 | 12 shares of Common Stock acquired at $3.54. |
| 09/15/2025 | 12 shares of Common Stock acquired at $3.50. |
| 09/16/2025 | 12 shares of Common Stock acquired at $3.50. |
| 09/17/2025 | 12 shares of Common Stock acquired at $3.38. |
| 09/18/2025 | 12 shares of Common Stock acquired at $3.31. |
| 09/19/2025 | 12 shares of Common Stock acquired at $3.34. |
| 09/22/2025 | 12 shares of Common Stock acquired at $3.29. |
| 09/23/2025 | 12 shares of Common Stock acquired at $3.21. |
| 09/24/2025 | 12 shares of Common Stock acquired at $3.10. |
| 09/25/2025 | 12 shares of Common Stock acquired at $3.10. |
| 09/26/2025 | 12 shares of Common Stock acquired at $3.05. |
| 09/29/2025 | 13 shares of Common Stock acquired at $3.14. |
| 09/30/2025 | Latest transaction date, 13 shares of Common Stock acquired at $3.12. |
| 10/03/2025 | Date the Form 4 filing was signed. |
Keywords
CPIX, Cumberland Pharmaceuticals, A.J. Kazimi, Insider Trading, Form 4, Stock Purchase, 10b5-1 Plan, Common Stock, Director, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.